BROOKS vs JAGSNPHARM: Stock Comparison
JAGSONPAL PHARMACEUTICALS is the larger company by market capitalisation. BROOKS LAB shows a lower P/E, a higher ROE and a higher net margin, while JAGSONPAL PHARMACEUTICALS shows a higher dividend yield, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BROOKS leads 6; JAGSNPHARM leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BROOKS | JAGSNPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BROOKS | JAGSNPHARM |
|---|---|---|
| Live Price | ₹65.69 | ₹232.89 |
| Day Change | 2.88% | -0.04% |
| Volume | 1.02 L | 51,421 |
| 52-Week High | ₹163.9 | ₹264.5 |
| 52-Week Low | ₹36.3 | ₹155 |
| Distance from 52W High | -59.92% | -11.95% |
Valuation
| Metric | BROOKS | JAGSNPHARM |
|---|---|---|
| Market Cap | ₹195 Cr | ₹1,537 Cr |
| P/E Ratio | 8.22x | 34.02x |
| P/B Ratio | 1.65x | 5.64x |
| EPS | ₹0.48 | ₹2 |
| Book Value | ₹41.64 | ₹41.95 |
| Dividend Yield | 0% | 2.78% |
Growth
| Metric | BROOKS | JAGSNPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | -6.37% | 9.6% |
| EPS Growth (TTM YoY) | 0% | 23.8% |
| Qtr Sales Growth | 0% | -71.37% |
| Qtr Profit Growth | 179.39% | -69.39% |
Profitability & Leverage
| Metric | BROOKS | JAGSNPHARM |
|---|---|---|
| ROE | 20.04% | 15.6% |
| ROCE | 5.38% | 16.48% |
| Net Margin | 28.67% | 15% |
| Operating Margin | 7.74% | 20.38% |
| Debt to Equity | 0.06x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BROOKS | JAGSNPHARM |
|---|---|---|
| Promoter Holding | 52.62% | 25.55%▲ 0.43 pp |
| FII Holding | 0%▼ 0.17 pp | 2.3%▼ 0.14 pp |
| DII Holding | 10.38% | 0.62%▲ 0.4 pp |
| Public Holding | 37%▲ 0.16 pp | 28.03%▼ 1.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BROOKS LAB and JAGSONPAL PHARMACEUTICALS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.